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Objectives This study sought to determine whether the evaluation of the combined presence of coronary artery calcium
(CAC) and high-sensitivity C-reactive protein (hsCRP) improves discrimination and stratification of hard coronary
events and all-cause mortality in the general population.
Background Coronary atherosclerosis is a chronic inflammatory disease. Both hsCRP as a measure of inflammation and CAC
as a measure of coronary plaque burden have been shown to improve risk appraisal.
Methods Framingham risk variables, hsCRP, and CAC were measured in 3,966 subjects without known coronary artery
disease or acute inflammation. After 5 years, incident coronary deaths, nonfatal myocardial infarction, and all-
cause mortality were determined.
Results CAC and hsCRP independently predicted 91 coronary events (adjusted hazard ratios [HRs]: log2(CAC1)  1.25
[95% confidence interval (CI): 1.16 to 1.34], p  0.0001; hsCRP  1.11 [95% CI: 1.02 to 1.21], p  0.019) and
130 deaths (adjusted HRs: log2(CAC1)  1.12 [95% CI: 1.06 to 1.19], p  0.0001; hsCRP  1.11 [95% CI:
1.04 to 1.19], p  0.004). For coronary events, net reclassification improvement (NRI) was 23.8% (p  0.0007)
for CAC and 10.5% (p  0.026) for hsCRP. Adding CAC to Framingham risk variables and hsCRP further im-
proved discrimination of coronary risk but not vice versa. Among persons without CAC, those with hsCRP 3
mg/l versus 3 mg/l had a significantly higher coronary risk (p  0.006). For all-cause mortality, integrated dis-
crimination improvement (IDI) was positive when CAC or hsCRP were added to age and sex (0.51%, p  0.001
and 0.43%, p  0.012, respectively). Adjusted HRs in the highest versus lowest category of a risk index de-
rived from established CAC and hsCRP thresholds (i.e., CAC  100 and hsCRP  3 mg/l) were 5.92 (95% CI:
3.14 to 11.16) for coronary events and 3.02 (95% CI: 1.82 to 5.01) for all-cause mortality (p  0.0001 each).
The adjusted HR for coronary events in intermediate risk subjects was 6.98 (95% CI: 2.47 to 19.73), p  0.001.
Conclusions The risk of coronary events and all-cause mortality that is mediated by the presence of coronary atherosclerosis and
systemic inflammation can be estimated by CAC and hsCRP. An improvement in coronary risk prediction and discrim-
ination was predominantly driven by CAC, whereas hsCRP appears to have a role especially in persons with very low
CAC scores. (J Am Coll Cardiol 2011;57:1455–64) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.10.043Atherosclerosis is a chronic inflammatory disease responsi-
ble for the majority of coronary events and deaths in the
Western world (1,2). Traditional coronary risk stratification
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plaque burden have both been
shown to improve risk appraisal
in individuals (3–7).
High-sensitivity CRP is a sys-
temic marker of inflammation and
has been found in many (8–10),
but not all (11,12), studies to be an
independent predictor of cardio-
vascular events and of all-cause
mortality (13). It has also been
suggested to be useful in guiding
treatment decisions (14). How-
ever, the predictive value of CRP
for risk stratification when added
to the Framingham risk score re-
mains controversial (10,15–17).
Coronary artery calcium is an
estimate of overall coronary ar-
tery plaque burden and an inde-
pendent predictor of coronary
events and of all-cause mortality
(3–5,18–20). Yet, little is known
about whether and how hsCRP
modifies the predictive value of
CAC and vice versa. The corre-
lation between CAC and CRP is
weak and largely determined by the presence of risk factors
(21), which suggests an independent role of atherosclerosis
burden and inflammation in event manifestation. Yet, few
studies have thus far assessed the predictive value of the
combined presence of elevated CAC and CRP for coronary
events. These studies yielded conflicting results (22,23), and
their combined role for predicting all-cause mortality has not
been studied.
See page 1465
The Heinz Nixdorf Recall (HNR) study is a population-
based cohort study designed to assess the predictive value of
novel markers of risk when used in addition to traditional risk
factors (3,24). The aim of this study was to determine the value
of hsCRP and CAC and their combination in extended
coronary event and all-cause mortality risk appraisal.
Methods
Participants. Participants were randomly selected from
mandatory city registries in Essen, Bochum, and Mülheim,
and invited to participate in the study as previously reported
(3,24). Physician- or self-referral was not allowed to avoid
selection bias. A total of 4,814 subjects aged 45 to 75 years
(50% females) were included between December 2000 and
August 2003. All subjects with physician-diagnosed coro-
nary artery disease, that is, a history of myocardial infarction
Abbreviations
and Acronyms
AUC  area under the
curve
BMI  body mass index
CAC  coronary artery
calcium
CI  confidence interval
CVD  cardiovascular
disease
EBCT  electron-beam
computed tomography
FRS  Framingham risk
score
HDL  high-density
lipoprotein
HR  hazard ratio
hsCRP  high-sensitivity
C-reactive protein
IDI  incremental
discrimination improvement
LDL  low-density
lipoprotein
NRI  net reclassification
improvementor coronary revascularization (n  327) were excluded from 4the study. Of the remaining participants, n  34 (0.8%)
ere lost to follow-up, in n  94 (2.1%), we were unable to
btain 5-year primary end point information, and in n 
44 (5.4%), 1 or more measurements of cardiovascular risk
actors, hsCRP, or CAC were unavailable. Subjects with
sCRP 10 mg/l suggesting acute inflammation were
xcluded (n  149, 3.3%), leaving 3,966 subjects (53%
omen) for this analysis. All participants provided written
nformed consent, and the study was approved by the ethical
ommittee at the University Essen, Germany.
ardiovascular risk factors and questionnaires. Blood
ressure was determined from the mean value of the second
nd third of 3 measurements taken at least 3 min apart
Omron 705-CP, OMRON, Mannheim, Germany) and
lassified according to the Seventh Report of the Joint
ational Committee on Prevention, Detection, Evaluation,
nd Treatment of High Blood Pressure (JNC-VII) thresh-
ld values (25). Body mass index (BMI) was calculated from
tandardized measurements of height and weight. Current
moking was defined as a history of cigarette smoking during
he past year. Standard enzymatic methods were used to
easure total cholesterol, low-density lipoprotein (LDL) and
igh-density lipoprotein (HDL) cholesterol, and triglycerides.
articipants were considered diabetic if they reported a physi-
ian diagnosis of diabetes or were taking antidiabetic medica-
ion. From these risk factors, the Framingham risk score (FRS)
i.e., predicted 10-year risk) was computed (26). High-
ensitivity CRP was measured using a standardized assay
Roche Diagnostics, Basel, Switzerland).
All subjects were queried about known cardiovascular
isease (CVD) using a physician-based questionnaire and
bout regular cardiovascular medication including antihy-
ertensive medication, lipid-lowering drugs, platelet aggre-
ation inhibitors, or glycosides.
lectron-beam computed tomography (EBCT). To
uantify CAC, nonenhanced EBCT scans were performed
ith a C-150 scanner (GE Imatron, South San Francisco,
alifornia). Prospective electrocardiogram triggering was
one at 80% of the RR interval. Contiguous 3-mm-thick
lices to the apex of the heart were obtained in both studies
t an image acquisition time of 100 ms. Coronary artery
alcium was defined as a focus of at least 4 contiguous pixels
ith a CT density 130 Hounsfield units. The CAC
gatston score was computed by summing the CAC scores
f all foci in the epicardial coronary system (27). Neither the
AC score nor hsCRP values were communicated to either
he participants or their treating physicians.
combined risk index based on hsCRP and CAC. An
ndex for the combined assessment of atherosclerosis burden
nd inflammation was defined based on previously defined
nd clinically used thresholds (28), that is, CAC  100 and
hsCRP  3.0 mg/l, resulting in 4 possible combinations:
) hsCRP 3 mg/l and CAC 100; 2) hsCRP 3 mg/l
nd CAC 100; 3) hsCRP 3 mg/l and CAC 100; and
) hsCRP 3 mg/l and CAC 100.
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March 29, 2011:1455–64 Coronary Calcium and hsCRP to Predict Hard EventsFollow-up. Annual postal questionnaires assessed the mor-
bidity status during follow-up, that is medication, hospi-
al admissions, outpatient diagnoses of CVD. Self-
eported incident cardiovascular morbidity and of fatal
vents was validated by review of hospital records and
ecords of the attending physicians (see the following
ext). All death certificates of the 3 cities under study
ere regularly screened. In parallel, deceased participants
ere tracked back to obtain as much information as
ossible to verify causes of death.
Participants were followed for a median of 5.0 years
5.1  0.3 years). The vital status could be obtained from
9.2% of subjects and information on primary end points
rom 97.1% of subjects.
tudy end points and verification of study end points.
rimary end points for this study were based on unequivo-
ally documented incident coronary events that met pre-
efined study criteria (3,24). We considered a myocardial
nfarction event based on symptoms, electrocardiographic
igns, and enzymes (levels of creatine kinase [CK-MB]) as
ell as troponin T or I, and necropsy as: 1) nonfatal acute
yocardial infarction; and 2) coronary death, which oc-
urred between the baseline examination and 5 years after
tudy entry (29).
For all primary study end points, hospital and nursing
ome records including electrocardiograms, laboratory val-
es, and pathology reports were collected. For deceased
ubjects, death certificates were collected, and interviews
ith general practitioners, relatives, and eyewitnesses were
ndertaken where possible. Medical records were obtained
or all reported end points. An external criteria and end
oint committee blinded for conventional risk factor status
nd CAC scores reviewed all documents and classified the
nd points thereafter.
tatistical analysis. Demographic data and risk factors
are expressed as mean  SD or median (25th, 75th
ercentile), frequencies are given as counts (%). Differ-
nces in proportions were statistically evaluated using
hi-square or Fisher exact test, trends in proportions
sing the Cochran-Armitage trend test; location mea-
ures of continuous quantities were compared using
tudent t test or Mann-Whitney U statistics.
The FRS categories were10%, 10% to 20%, and20%
of 10-year predicted coronary heart disease risk. Observed
5-year cumulative risks are given in FRS and predefined
CAC score categories 0, 1 to 99, 100 to 399, and 400 as
well as FRS and hsCRP categories 1, 1 to 3, and 3 mg/l
(24,27). Cumulative coronary event risks are also calculated
stratified by the FRS and the combined risk index. Kaplan-
Meier estimates of coronary event-free rates as well as
overall survival were calculated in strata defined by the
combined risk index. We used multivariable Cox propor-
tional hazard regression to calculate unadjusted and
adjusted hazard ratios (HRs) and corresponding 95%
confidence intervals (CIs) with respect to CAC catego-
ries, hsCRP categories, or the combined risk index, forthe time to occurrence of end points. Adjustment ac-
counted for FRS, presence of any cardiovascular disease
or cardiovascular medication, for BMI, and also for
hsCRP for the model with CAC, or for the logarithmic
transform of CAC, log(CAC1), for the model with
hsCRP. Schoenfeld residuals were calculated to evaluate
the validity of the proportional hazards assumption (30).
To estimate the increase in prediction accuracy, we used
logistic regression to calculate the receiver-operator char-
acteristic curves and the area under the receiver-operator
characteristic curves (AUC or c-statistic) including 95%
confidence intervals and compared the AuC based on the
FRS alone, the AuC when adding the log-transformed
CAC score or hsCRP, and finally, when adding log-
(CAC1) and hsCRP to the FRS (31). This was also
carried out for a model with Framingham risk variables
(age, sex, diabetes, systolic blood pressure, LDL and
HDL cholesterol, present smoking status) with and
without log(CAC1) and/or hsCRP. The latter models
also served to estimate the integrated discrimination
improvement (IDI) (32). The same route was followed
for all-cause mortality, but with the model consisting of
age and sex as the starting point. Net reclassification
improvement (NRI) was computed for coronary events
(32), but not for all-cause mortality as no predefined
thresholds for low, intermediate, or high risk have been
published. Rescaled individual predicted risks from mod-
els with and without log(CAC1) and/or hsCRP were
compared with established Framingham risk thresholds.
The rescaling factor was derived by dividing the average
10-year Framingham risk, that is, 11.29%, by the ob-
served 5-year event rate, that is, 2.29%, yielding a
rescaling factor of 4.92. In addition to the AUCs, we
computed Harrell’s c-statistics for time-to-event data
(33). To evaluate model calibration, we calculated the
Hosmer-Lemeshow chi-square. All calculations were
performed with SAS version 9.2 (Cary, North Carolina).
Results
Incidence of coronary events and all-cause mortality. After
5.1.  0.3 years of follow-up, 91 subjects experienced
coronary events. Twenty-nine subjects (31% women) died
of coronary heart disease, and 62 subjects (29% women) had
a nonfatal myocardial infarction. Of those with nonfatal
myocardial infarction as their first event, 4 died later, 3 of
coronary causes. In addition, 98 noncoronary deaths oc-
curred (main cause: 54 cancer-related deaths). Table 1
shows characteristics of subjects with and without coronary
events. Deceased persons also had higher Framingham risk
scores (median [Q1/Q3]: 14 [9/22] vs. 9 [6/14], p 
0.0001), higher CAC scores (73 [9/372] vs. 11 [0/106], p
0.0001), and higher hsCRP values (2.2 [1.1/4.4] vs. 1.4
[0.7/2.8], p  0.0001).
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using CAC or hsCRP. Crude and adjusted HRs of coronary
events and of all-cause mortality increased with increasing
CAC and hsCRP categories (Table 2) and reached statistical
significance with CAC 100 or hsCRP 3 mg/l for
coronary events and with CAC 0 or hsCRP 1 mg/l
for all-cause mortality. Adjusted HRs of all-cause mor-
tality (as in Table 2, Model 2) were not much different
when coronary deaths were excluded (data not shown).
In multivariable Cox regression models including known
Distribution of Risk Variables in Subjects With VThose W thout Coron ry Ev nts D ring 5 YearsTable 1 Distribution of Risk Va ables in SubThose Without Coronary Events Dur
No Coronary
n 3,875
Age, yrs 59.2 7
Female 53.
BMI 27.7 4
Systolic BP, mm Hg 133 2
Diastolic BP, mm Hg 81 1
Hypertension 53.
Total cholesterol, mg/dl 231 3
LDL cholesterol, mg/dl 146 3
HDL cholesterol, mg/dl 59 1
Smoking status
Never 44.
Current 22.
Former 33.
Diabetic 7.
CV medication* 35.
Lipid-lowering drugs 9.
Antihypertensive medication 31.
Cardiovascular diseases 23.
FRS
10-yr FRS 11.1 8
Median (Q1–Q3) 9 (6–14
10% in 10 yrs 55.
10–20% in 10 yrs 32.
20% in 10 yrs 12.
CAC score
Median (Q1–Q3) 11 (0–10
0 32.
0–99 41.
100–399 16.
400 9.
hsCRP, mg/l
Median (Q1–Q3) 1.4 (0.7–
1 35.
1–3 42.
3 22.
Combined risk index
I: hsCRP 3, CAC 100 58.
II: hsCRP 3, CAC 100 15.
III: hsCRP 3, CAC 100 19.
IV: hsCRP 3, CAC 100 6.
Values are mean  SD or % unless otherwise indicated. *CV medicat
BMI body mass index; BP blood pressure; CAC coronary arte
score; HDL  high-density lipoprotein; hsCRP  high-sensitivity C-reacCVD, cardiovascular medication, the FRS, BMI, CAC,and hsCRP, both CAC and hsCRP remained predictors of
coronary events: HR: 1.25 (95% CI: 1.16 to 1.34), p 
.0001 for log2(CAC1) and HR: 1.11 (95% CI: 1.02 to
1.21), p  0.019 for hsCRP. CAC and hsCRP were also
independent predictors of all-cause mortality (HR: 1.12
[95% CI: 1.06 to 1.19], p  0.0001 for log2(CAC1) and
R: 1.11 [95% CI: 1.04 to 1.19], p  0.004 for hsCRP).
hese estimates did not change much when coronary deaths
ere excluded (data not shown). In a model including
og2(CAC1), hsCRP, and their product, we found no
sllow-UpWith Versus
Years of Follow-Up
s Coronary Events p Value
91
62.8 8.2 0.0001
29.7 0.0001
28.2 4.4 0.29
143 23 0.0001
83 12 0.082
67.0 0.013
238 38 0.10
155 35 0.019
54 17 0.006
36.2
27.5 0.29
36.3
17.6 0.0001
51.7 0.0013
11.0 0.54
47.3 0.001
23.1 0.90
17.6 11.4 0.0001
14 (9–24)
27.5
40.7 0.0001
31.9
182 (31–982) 0.0001
12.1
26.4
0.000125.3
36.3
2.1 (0.9–4.8) 0.0007
25.3
34.1 0.0003
40.7
24.2
0.0001
14.3
35.2
26.4
udes blood pressure lowering or lipid-lowering medication.
m; Chol cholesterol; CV cardiovascular; FRS  Framingham risk
tein; Hx  history; LDL  low-density lipoprotein; Q  quartile.ersuof Foject
ing 5
Event
.7
4
.5
1
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9
9
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March 29, 2011:1455–64 Coronary Calcium and hsCRP to Predict Hard Events(HR: 0.99 [95% CI: 0.96 to 1.01], p 0.26) or for all-cause
ortality (HR: 1.00 [95% CI: 0.98 to 1.02], p  0.66). In
none of these models was a deviation from the proportional
hazards assumption detected.
Measures of discrimination (c-statistics, IDI, NRI).
Upon adding CAC to the model based on Framingham risk
factors for coronary event risk assessment, AUCs, IDI, and
NRI indicated improvement, whereas when adding hsCRP,
only NRI, but not AUCs and IDI, showed discrimination
improvement (Table 3). Calibration (Hosmer-Lemeshow)
yielded a chi-square of 11.5 (p  0.18) for the model with
Framingham risk variables. This value decreased to 7.1 (p 
0.53) when log(CAC1) and hsCRP were entered into the
model. Adding CAC to the model based on Framingham risk
factors and hsCRP further improved discrimination as indi-
cated by AUCs, IDI, and NRI, whereas adding hsCRP to the
model based on Framingham risk factors and CAC did not
(Table 3).
Adding CAC to the model based on age and sex or to
the model based on age, sex, and hsCRP to predict
Crude and Adjusted HR (95% CI) of Coronary Events and All-CauseTable 2 Crude and Adjusted HR (95% CI) of Coronary Events a
Coronary Events
Crude HR (95% CI)
Adjusted HR (95% CI)
Model 1
Adjusted HR
Mode
CAC score
0 1.0 1.0 1.0
0–99 1.75 (0.86–3.58) 1.47 (0.71–3.05) 1.48 (0.72–
100–399 4.19 (2.04–8.59) 3.01 (1.43–6.33) 3.03 (1.44–
400 10.37 (5.24–20.52) 6.00 (2.86–12.59) 5.92 (2.82–
hsCRP, ml/l
1 1.0 1.0 1.0
1–3 1.19 (0.65–1.92) 0.95 (0.55–1.65) 0.95 (0.55–
3 2.56 (1.52–4.31) 1.98 (1.14–3.43) 1.82 (1.05–
Model 1: adjusted for FRS, known CV disease or CV medication and BMI. Model 2: adjusted for FR
CI  confidence interval; HR  hazard ratio; other abbreviations as in Table 1.
c-Statistics, IDI, and NRI for the Combined Assessment of TraditionhsCRP, and log(CAC1) in Predicting Coronary Events and All-CauTable 3 c-Statistics, IDI, and NRI for the Combi ed AssessmenhsCRP, and log(CAC1) in Predicting Coronary Events
Model No. Model
Corona
Model Based on Fram
c-Statistics
1. Base model alone 0.719 (0.671–0.767)
2. 1.  hsCRP 0.732 (0.684–0.780)
p value vs. model 1 0.12
3. 1.  log(CAC1) 0.763 (0.715–0.812)
p value vs. model 1 0.0067 
4. 1.  hsCRP and log(CAC1) 0.771 (0.724–0.819) 0.161
0.146
0.013
p value vs. model 1 0.0014
p value vs. model 2 0.014 
p value vs. model 3 0.12
Net reclassification improvement (NRI) was computed for coronary events only, because of the lack
nd for CAC was 19.8% (p  0.003) when lower and upper intermediate risk thresholds were defi
ressure, LDL and HDL cholesterol, and present smoking status.
IDI  incremental discrimination improvement; other abbreviations as in Table 1.all-cause mortality resulted in positive IDIs, whereas
improvements in the AUCs were marginal (Table 3).
Adding hsCRP to the model based on age and sex
significantly increased AUC with IDI being positive.
Also, hsCRP further increased AUC with IDI being
positive when added to the model based on age, sex, and
CAC (Table 3). For all-cause mortality, calibration
yielded a chi-square of 12.9 (p  0.11) for the model
with age and sex. This value decreased to 7.1 (p  0.52)
when log(CAC1) and hsCRP were entered into the
model.
The c-statistics from time-to-event analyses (Harrell’s c), as
well as IDI and NRI from time-to-event analysis, were
numerically almost identical to c-statistics, IDI, and NRI from
logistic regression for both end points (data not shown).
Coronary risk and all-cause mortality stratified by CAC
and hsCRP categories and a risk index derived from
CAC and hsCRP categories. In each hsCRP category,
adjusted HRs of coronary events and of all-cause mortality
generally increased with each CAC category and vice versa
ality in the CAC and hsCRP Categoriesl-Cause Mortality in the CAC and hsCRP Categories
All-Cause Mortality
CI)
Crude HR (95% CI)
Adjusted HR (95% CI)
Model 1
Adjusted HR (95% CI)
Model 2
1.0 1.0 1.0
2.94 (1.66–5.20) 2.44 (1.36–4.37) 2.45 (1.37–4.38)
4.10 (2.21–7.59) 2.82 (1.49–5.36) 2.82 (1.48–5.36)
) 6.54 (3.51–12.21) 3.79 (1.94–7.42) 3.71 (1.89–7.28)
1.0 1.0 1.0
1.87 (1.16–2.99) 1.71 (1.05–2.79) 1.72 (1.06–2.79)
3.10 (1.91–5.01) 2.63 (1.57–4.38) 2.53 (1.52–4.23)
wn CV disease or CV medication, BMI, and hsCRP or CAC.
arkers of Risk,o talityraditional Markers of Risk,
All-Cause Mortality
nts All-Cause Mortality
m Risk Variables* Model Based on Age and Sex
NRI c-Statistics IDI
/ 0.695 (0.647–0.743) /
5 10.5% 0.712 (0.666–0.758) 0.0043
0.026 0.044 0.012
8 23.8% 0.706 (0.660–0.752) 0.0051
1 0.0007 0.21 0.0006
del 1 20.5% vs. model 1 0.719 (0.675–0.763) 0.0090 vs. model 1
del 2 13.3% vs. model 2 0.0047 vs. model 2
del 3 2.2% vs. model 3 0.0039 vs. model 3
1 0.0027 0.025 0.0003
1 0.031 0.33 0.0014
0.50 0.067 0.023
blished thresholds of risk for all-cause mortality. Note that the NRI for hsCRP was 6.8% (p 0.053)
6% and 20% in 10 years. / indicates not applicable. *Including age, sex, diabetes, systolic bloodMortnd Al
(95%
l 2
3.07)
6.38)
12.45
1.64)
3.15)al Mset of T
and
ry Eve
ingha
IDI
/
0.001
0.32
0.014
0.000
vs. mo
vs. mo
vs. mo
0.000
0.000
0.44
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Coronary Calcium and hsCRP to Predict Hard Events March 29, 2011:1455–64(Fig. 1). Cumulative risks of coronary events and of all-
cause mortality increased with increasing CAC scores
within each hsCRP category (cumulative risks not shown,
p  0.0001 for trend each). In the lowest and in the
highest CAC categories, the cumulative risk was higher
for those with hsCRP 3 mg/l versus hsCRP 3 mg/l
(p  0.006 and p  0.017, respectively). The increase in
cumulative all-cause mortality risk observed for increas-
ing hsCRP categories was significant within the 2 highest
CAC categories (p  0.007 and p  0.007 for trend,
respectively).
Coronary event-free rates and overall survival decreased
with increasing CAC, hsCRP, and risk index categories
(Fig. 2). When coronary deaths were excluded from analysis
of all-cause mortality, adjusted HRs for the risk index did
not change much, that is, to 1.0, 1.37 (95% CI: 0.76 to
2.45), 0.91 (95% CI: 0.51 to 1.62), and 2.67 (95% CI: 1.51
to 4.74).
The comparison of c-statistics and IDI for the risk
Figure 1
Adjusted HRs of Coronary Events
and of All-Cause Mortality in the Different
Combinations of CAC and hsCRP Categories
(A) Coronary events and (B) all-cause mortality, with coronary artery calcium
(CAC)  0 and high-sensitivity C-reactive protein (hsCRP) 1 mg/l as the refer-
ence category. Hazard ratios (HRs) were adjusted for the Framingham risk
score, known cardiovascular disease, cardiovascular medication, and body
mass index. *Significant difference from the reference category.index compared with CAC categories did not show any vstatistically significant differences either for coronary
event risk or for all-cause mortality risk (p  0.1 each).
Coronary risk in different Framingham risk score categories.
Within each Framingham risk category, the cumulative
coronary event risk increased with increasing CAC, hsCRP,
and risk index categories (Figs. 3A to 3C). Of note, in each
Framingham risk category, event rates were similarly low
when CAC was 100 and hsCRP 3 mg/l (Fig. 3C). In
ntermediate-risk subjects, coronary event-free rates were
imilar when intermediate risk was defined as a risk between
% and 20% in 10 years (Figs. 4A to 4C).
iscussion
his study shows that the risk of coronary events and
ll-cause mortality that is mediated by the presence of
oronary atherosclerosis and systemic inflammation can
e estimated by measuring CAC and hsCRP, and that
heir combined assessment can be used for improved risk
tratification and discrimination in the general popula-
ion. Adding CAC or hsCRP to traditional risk factors
mproved coronary and all-cause mortality risk stratifica-
ion in a magnitude comparable to previous prospective
tudies (3,4,6). The ability of CAC to improve discrim-
nation and net reclassification of coronary risk was
uperior to that of hsCRP, and CAC further improved
easures of coronary risk discrimination when added to
ramingham risk variables and hsCRP, whereas adding
sCRP to Framingham risk variables and CAC did not.
et, in subjects without CAC, hsCRP was associated
ith a relevant increase in coronary risk. Both CAC and
sCRP were of similar and additive value for improved
iscrimination of all-cause mortality. A simple, previ-
usly suggested risk index (28) derived from established
AC and hsCRP thresholds also identified many persons
t clearly elevated or low risk, but it did not improve
verall discrimination beyond CAC scoring.
Three studies directly compared the predictive values
f CRP (but not hsCRP) and CAC. First, 967 nondia-
etic subjects, mostly men with an average age of 66
ears, who experienced coronary events during 6.4 years
ollow-up had much higher CAC scores (p  0.0001)
nd higher CRP values (p  0.007) than those without,
ut the independent effect of CRP was of borderline
ignificance (23). Second, in 4,903 asymptomatic persons
f the St. Francis Heart Study age 50 to 70 years, CRP
id not contribute to coronary event prediction after
djustment for standard risk factors and the baseline
AC score (22). Third, in a preliminary report from the
ESA (Multi-Ethnic Study of Atherosclerosis) (34),
ully adjusted HRs for CVD events were 1.41 (95% CI:
.98 to 2.04) for CRP 3 mg/l compared with 1 mg/l.
nterestingly, as in our study, the coronary event risk was
uch higher in subjects with low CAC scores and highersus low CRP values (34). In contrast to our study, the
1461JACC Vol. 57, No. 13, 2011 Möhlenkamp et al.
March 29, 2011:1455–64 Coronary Calcium and hsCRP to Predict Hard Eventslatter 2 studies used broader coronary event definitions,
CRP but not hsCRP was measured, and none of these 3
studies have evaluated the joint effect of CAC and CRP
on all-cause mortality.
There is an ongoing debate on the value of including
markers of atherosclerosis and inflammation into tradi-
tional risk assessment (17,21,35). A combined approach
appears promising as coronary plaque burden and sys-
temic inflammation seem to have distinct roles in the
pathogenesis of different events. Although CAC is a
Figure 2 Coronary Event-Free Rates and Overall Survival Stratifi
(A, C, E) shows the coronary event-free rates and (B, D, F), overall survival. HRs
known cardiovascular disease, cardiovascular medication, and body mass index. Asurrogate of overall coronary atherosclerosis burden, butnot necessarily of vulnerable plaque, systemic inflamma-
tion may predispose to a higher likelihood of plaque
rupture and thrombosis (21). As coronary events
predominantly occur in the presence of extensive coro-
nary plaque burden (36), a high CAC score had a
particularly strong impact in predicting coronary events.
hsCRP contributed to risk assessment in subjects with
little or no coronary atherosclerosis, where fewer events
occurred.
All-cause mortality is only in part determined by CVD
y CAC, hsCRP, and a Risk Index Derived From CAC and hsCRP
djusted for the Framingham risk score,
iations as in Figure 1.ed b
were a
bbrevevents, and the predictive value of CAC was accordingly lower
1462 Möhlenkamp et al. JACC Vol. 57, No. 13, 2011
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Cumulative Observed 5-Year Coronary Event
Risks Within FRS Categories Stratified by
CAC, hsCRP, and the Risk Index
(A) CAC, (B) hsCRP, and (C) the risk index. Within the intermediate Framingham
risk score (FRS) category, defined as 10% to 20% risk in 10 years, HRs in the sec-
ond, third, and fourth compared with the first risk category were for CAC: 2.14
(95% confidence interval [CI]: 0.47 to 9.82), 2.68 (95% CI: 0.79 to 17.09), and
10.34 (95% CI: 2.34 to 45.66); for hsCRP: 1.09 (95% CI: 0.47 to 2.54) and 2.01
(95% CI: 0.84 to 4.82); and for the risk index: 2.38 (95% CI: 0.75 to 7.57), 3.84
(95% CI: 1.58 to 9.36), and 6.98 (95% CI: 2.47 to 19.73), respectively. p values
for trend within FRS categories. Note that the cumulative 5-year event rates were
very similar in all 3 FRS categories when both CAC and hsCRP were low, that is,
0.9% (95% CI: 0.5% to 1.5%), 1.1% (95% CI: 0.5% to 2.3%), and 1.2% (95% CI:
0.2% to 4.3%), respectively. Abbreviations as in Figure 1.Figure 4
Coronary Event-Free Rates in Intermediate-Risk
Subjects Stratified by CAC, hsCRP, and the
Risk Index Derived From CAC and hsCRP
(A) CAC, (B) hsCRP, and (C) the risk index. Intermediate risk is defined as 6%
to 20% predicted coronary event risk in 10 years. HRs were adjusted for the
Framingham risk score, known cardiovascular disease, cardiovascular medica-
tion, and body mass index. Abbreviations as in Figure 1.
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theless, the independent predictive value of CAC for all-cause
mortality is in line with earlier and recent angiography-based
(37) and other CAC-based studies (18,38,39). Likewise,
sCRP contributed considerably to the assessment of all-cause
ortality risk, which is in agreement with a recent multibio-
arker study, where CRP was of little value for coronary risk
rediction (40), while being an important predictor of all-cause
ortality (40).
Taken together, elevated levels of CAC and hsCRP
ot only provide evidence of advanced coronary athero-
clerosis and systemic inflammation, but in their pres-
nce, comorbidities seem to be associated with a greater
isk of death. This is clinically relevant, as the risk from
therosclerosis burden can effectively be treated especially
sing statins (41). In addition, the Jupiter trial suggested
hat not only the coronary event risk, but also the risk of
ll-cause mortality may be reduced by targeting inflam-
ation (14).
tudy limitations. hsCRP is a nonspecific marker of in-
ammation. Other inflammatory markers such as Il-6 may
rovide valuable additional prognostic information.
In this study, data were acquired using EBCT scan-
ers. MESA found equivalent reproducibilities for mea-
uring CAC using EBCT and multidetector row helical
omputed tomography (MSCT) (42) and direct compar-
son studies also yielded comparable CAC quantities in
BCT versus MSCT (43), which suggests that our
ndings can be used clinically for data acquired on most
SCT scanners.
Our data suggest that extended risk assessment im-
roves risk stratification and can guide decision making,
specially in intermediate-risk individuals. Whether
AC- and hsCRP-driven risk-modifying therapy is jus-
ified by improved outcome must be tested in clinical
rials. First-line recommendation in asymptomatic sub-
ects remains a healthy lifestyle including smoking cessa-
ion, regular physical activity, weight control, and a
ealthy diet. The efforts that are necessary to implement
ffective lifestyle modification in larger cohorts must be
eighed against the costs of extended risk assessment and
he potential risk attributable to radiation exposure asso-
iated with CAC scoring.
onclusions
he risk of coronary events and all-cause mortality that is
ediated by the presence of coronary atherosclerosis and
ystemic inflammation can be estimated by CAC and
sCRP. The improvement in risk prediction and discrimi-
ation was predominantly driven by CAC, whereas hsCRP
ppears to have a role especially in persons with low CAC
cores.Reprint requests and correspondence: Dr. Stefan Möhlenkamp,
Cardiology Clinic, West-German Heart Center Essen, University
Clinic Duisburg-Essen, Hufelandstrasse 55, 45122 Essen, Ger-
many. E-mail: stefan.moehlenkamp@uk-essen.de.
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